Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Tumori ; 80(6): 459-63, 1994 Dec 31.
Article in English | MEDLINE | ID: mdl-7900236

ABSTRACT

AIMS AND BACKGROUND: High doses of metoclopramide are contraindicated to prevent chemotherapy-induced emesis in pediatric patients, since the incidence of extrapyramidal reactions is increased in these patients. The aim of this small study was to evaluate the antiemetic activity and the safety of tropisetron (a new selective antagonist of 5-HT3 receptors) in children who suffered nausea and vomiting during previous chemotherapy courses, despite the administration of an anxiolytic agent (hydroxyzine hydrochloride). METHODS: The children with a malignant neoplasm were treated for emesis with tropisetron (5 mg o.a.d. or b.i.d.) during a total of 20 cycles of chemotherapy with carboplatin combined with other antitumor agents. RESULTS: In 14 cycles (70%), there was no vomiting. There were two or less episodes of vomiting in 2 cycles (10%), 3-4 episodes in 2 cycles (10%), and no inhibition of vomiting at all in 2 cycles (10%). In 8 cycles there were no episodes of nausea (40%), in 5 cycles (25%) there were episodes of moderate nausea, and in 4 (20%) there were episodes of severe nausea. One child had a mild headache during one cycle and moderate hypotension during another. CONCLUSIONS: The results suggest that tropisetron is both efficacious and safe for the treatment of pediatric patients.


Subject(s)
Antiemetics/therapeutic use , Antineoplastic Agents/adverse effects , Indoles/therapeutic use , Nausea/prevention & control , Serotonin Antagonists/therapeutic use , Vomiting/prevention & control , Adolescent , Antineoplastic Agents/administration & dosage , Child , Child, Preschool , Drug Administration Schedule , Female , Humans , Infant , Male , Nausea/chemically induced , Neoplasms/drug therapy , Treatment Outcome , Tropisetron , Vomiting/chemically induced
2.
Recenti Prog Med ; 85(1): 22-8, 1994 Jan.
Article in Italian | MEDLINE | ID: mdl-8184176

ABSTRACT

Giant cell arteritis (GCA) or temporal arteritis is an entity of unknown aetiology and uncertain autonomy for the close relationship with polymyalgia rheumatica (PMR). This work describes four patients with GCA alone. All patients had clinical and laboratoristic evidence of the disease and were treated with steroids. The distribution of HLA antigens showed an increased occurrence of DR4 and B8 antigens. Unfortunately, the small number of patients and the short period of observation don't allow to prove the exact nature of the link between GCA and PMR.


Subject(s)
Giant Cell Arteritis/complications , Polymyalgia Rheumatica/complications , Aged , Female , Humans , Middle Aged , Polymyalgia Rheumatica/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...